

5th August, 2025

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir / Madam,

Subject: Update on USFDA inspection at Company's manufacturing facility in Bommasandra, Bengaluru, India

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 30th May, 2025, regarding the United States Food and Drug Administration ('USFDA') current Good Manufacturing Practices ('cGMP') inspection at the Company's manufacturing facility in Bommasandra, Bengaluru from 26th to 30th May, 2025, we hereby notify that the USFDA, via email communication dated 4th August, 2025 (23.59 Hrs IST), has classified the above-referred inspection as Voluntary Action Indicated (VAI).

Please take the above information on record.

Thanking you,

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode